Study guide

3.1 Biological Effects of Radiation Exposure

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

3.1 Biological Effects of Radiation Exposure

Key Takeaways Explain This Topic AI

Deterministic (tissue) effects have a practical dose threshold and increase in severity with dose—examples include erythema (~200–600 rad / 2–6 Gy skin dose) and hematopoietic syndrome above roughly 200–300 rad whole-body

Stochastic effects (cancer, heritable risk) have no known threshold; risk is modeled with the linear no-threshold (LNT) model used by NRC and NCRP for radiation protection

The Law of Bergonié and Tribondeau: radiosensitivity rises with high mitotic rate, long proliferative future, and low differentiation—bone marrow, GI crypt cells, and the fetus are highly sensitive

Declared pregnancy limits aim to protect the embryo/fetus; fetal dose is tracked separately from the worker’s occupational TEDE under 10 CFR 20.1208

NMT occupational exposure is almost always chronic low-level; patient diagnostic doses are usually stochastic-risk only, while therapy (I-131, Lu-177, Ra-223) can approach deterministic thresholds in target tissues

Last updated: August 2026

Nuclear medicine technologists work daily with unsealed sources that emit photons, electrons, or alpha particles. Domain II of the CNMT exam expects you to distinguish how radiation harms tissue, who is being protected (patient vs worker vs fetus), and which effects drive regulation. This section builds the biological foundation for ALARA, dose limits, and surveys covered later in the chapter.

Deterministic (Tissue) Effects

Deterministic effects —also called tissue reactions —appear only after a practical threshold dose is exceeded. Above that threshold, severity increases with dose , and there is often a latency of hours to weeks depending on the tissue.

Classic examples relevant to medical radiation:

Effect Approximate threshold (order of magnitude) Notes for NMT practice

Transient erythema ~200 rad (2 Gy) acute skin dose Possible with prolonged fluoroscopy; rare with diagnostic NM

Temporary epilation ~300–600 rad (3–6 Gy) Temporary hair loss after high skin dose

Cataracts (historical acute estimates) tens of Gy acute to lens; chronic thresholds lower under modern data Lens dose limits exist partly for this reason

Hematopoietic syndrome ~200–300 rad (2–3 Gy) whole-body Bone marrow suppression; not expected from routine NM work

GI syndrome ~1,000 rad (10 Gy) whole-body Life-threatening; accident/weapons context

In nuclear medicine, diagnostic procedures are designed so that deterministic thresholds are not approached in patients or staff. Therapeutic radiopharmaceuticals (high-activity I-131 , Lu-177 , Ra-223 ) can deliver large local doses into deterministic territory on purpose while whole-body stochastic risk is managed separately.

Key exam phrase: deterministic = threshold + severity scales with dose .

Stochastic Effects

Stochastic effects are random in occurrence. Classic endpoints are cancer (somatic) and, theoretically, heritable effects . For protection purposes:

There is no known practical threshold below which risk is proven zero.

The probability of effect rises with dose; cancer severity does not “scale” the way burn severity does.

U.S. radiation protection (NRC/NCRP philosophy behind 10 CFR 20) uses the linear no-threshold (LNT) model: low-dose risk is assumed proportional to dose with no safe cutoff.

LNT is a conservative regulatory model , not a claim that every mrem causes cancer. Exam items test that you apply LNT for ALARA and dose limits , not epidemiology debates.

Patient vs Technologist Contexts

Who Typical exposure pattern Dominant concern

Patient (diagnostic) Occasional procedure (mSv-range effective dose varies by study) Stochastic risk justified by clinical benefit

Patient (therapy) High organ/tumor dose Target tissue reaction + whole-body stochastic risk; release rules

Technologist Chronic low-level, external ± internal Keep TEDE and extremity dose ALARA under occupational limits

Embryo/fetus Secondary if worker is pregnant Separate fetal dose limit once pregnancy is declared

Patients receive intentional medical exposure under a licensed authorized user; that justification does not excuse poor staff technique. Assay, administer, and shield so the patient gets the prescribed activity and staff receive as little dose as reasonably achievable.

Short-Term vs Long-Term Effects

Short-term (early) high-dose effects include nausea, fatigue, erythema, and marrow depression (hours to weeks)—deterministic when thresholds are crossed. Long-term (late) effects include cancer (years–decades latency), delayed cataracts, fibrosis, and potential heritable risk. Occupational NM work is managed almost entirely around late stochastic risk and fetal protection , not acute radiation sickness.

Exam time frames: hours–days after multi-Gy whole-body → prodromal/marrow syndromes; weeks after high skin dose → moist desquamation; years after lower cumulative doses → LNT cancer-risk framing.

Radiosensitivity: Law of Bergonié and Tribondeau

The Law of Bergonié and Tribondeau states that radiosensitivity is greater when cells are (1) highly mitotic , (2) have a long proliferative future , and (3) are poorly differentiated .

High sensitivity: lymphoid tissue, bone marrow stem cells, GI crypt cells, germ cells, and embryo/fetus . Lower sensitivity: muscle, mature bone/cartilage, and highly differentiated adult neural tissue (developing brain in utero is an important exception).

Cell-cycle note: late G2/M cells are generally more radiosensitive than late S-phase cells. After high whole-body dose, rapidly renewing tissues (marrow, then GI) fail first—classic Bergonié and Tribondeau application.

Fetal Sensitivity

Risk depends on gestational age and dose :

Preimplantation (~0–9 days): “all-or-none” lethality risk at high doses.

Organogenesis (~weeks 2–8): elevated teratogenic/structural risk at high doses.

Fetal period , especially ~8–15 weeks for CNS: concern for intellectual disability and growth effects after significant fetal dose. Appropriate diagnostic NM doses are usually far below those thresholds.

Once a worker declares pregnancy in writing , the licensee must keep embryo/fetus dose ≤ 0.5 rem (5 mSv) for the entire gestation (10 CFR 20.1208)—far below the adult occupational 5 rem (50 mSv)/year TEDE limit, reflecting fetal radiosensitivity.

Practical points: screen women of childbearing age before high-risk exams or therapy when protocol requires; never administer I-131 without pregnancy-status verification per policy; diagnostic studies may proceed when clinically justified with agent-specific fetal dose awareness.

  • Exam Hooks
  • Extreme local skin injury → deterministic (severity ↑ with dose)
  • Lifetime cancer risk after chronic mrem → stochastic / LNT
  • Marrow fails before muscle after acute whole-body dose → Bergonié and Tribondeau
  • Fetal limit 0.5 rem/gestation after declaration → high fetal radiosensitivity + separate limit